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Introduction 
Paroxysmal tonic spasms [PTS] are common in patients with neuromyelitis optica spectrum 
disorder (NMOSD).1 2 In patients with demyelinating disease, PTS can significantly reduce the 
quality of life, limit activities of daily living and the rehabilitative process following an acute 
relapse.3 
As in patients with multiple sclerosis (MS), paroxysmal tonic spasms in NMOSD usually 
respond well to treatment with carbamazepine.2 However, the optimal treatment in patients 
where carbamazepine is contraindicated or poorly tolerated is unclear. We describe a patient 
with NMOSD with severe paroxysmal tonic spasms who did not tolerate carbamazepine but 
was successfully treated with lacosamide (Vimpat). 
Case  
A 44 year old woman with NMOSD developed paroxysmal tonic spasms while recovering from 
an attack of transverse myelitis in August 2015. The tonic spasms were characterised by 
flexion of the right wrist and elbow, internal rotation of the shoulder and forced head deviation 
to the right side. Some of the attacks also involved the right leg. Dozens of episodes were 
occurring each day triggered by any movement of the right arm or head. She was initially 
treated for spasticity with escalating doses of baclofen, gabapentin and benzodiazepines 
without improvement.  
When it became apparent that the attacks were tonic spasms, she was started on 
carbamazepine with prompt resolution but five weeks later developed a generalised exfoliative 
erythematous rash. The clinical picture was consistent with Stevens-Johnson syndrome with 
toxic epidermal necrolysis. Carbamazepine was discontinued but within a week severe, 
frequent tonic spasms recurred.  
Alternative sodium-channel blocking agents such as oxcarbazepine, phenytoin and 
lamotrigine were felt to be contraindicated because of a shared risk of developing Stevens-
Johnson syndrome. She therefore commenced lacosamide 100mg daily and within 48 hours 
the tonic spasms were markedly improved and have subsequently ceased with no recurrence 
of the rash. 
Discussion  
PTS are stereotypical, recurrent, localized muscle spasms (in one or more limbs and/or the 
trunk), lasting between twenty seconds to three minutes, accompanied by severe pain and 
dystonia. They can have a significant impact on quality of life and rehabilitative potential thus 
require prompt diagnosis and treatment.3 They frequently occur in patients with longitudinally 
extensive transverse myelitis secondary to NMOSD.   
The pathophysiology of PTS is unclear and has been a matter of debate. In demyelinating 
disease, it is thought that demyelination renders axons hypersensitive to minor insults and 
subsequent irritation of these axons facilitates ephaptic transmission between demyelinated 
axons, resulting in PTS.4 It has also been hypothesized that dysfunctional ion channels are 
involved in facilitating ephaptic transmission which may explain why sodium-channel blockers 
- such as carbamazepine - have been successfully used to suppress PTS in both MS and 
NMOSD.5, 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TENS) account for the 
most severe forms of cutaneous adverse drug reaction. The pathophysiology of drug-induced 
SJS is not well understood, however, scientific observations indicate that CD8+ cytotoxic T-
cell mediated responses are integral to its pathogenesis.6    SJS is a rare but well described 
adverse reaction to carbamazepine.7 Because of the high rate of cross-reactivity with other 
commonly prescribed anticonvulsants and the previous failure of response to agents used for 
spasticity, treatment with lacosamide was tried. Lacosamide is a novel anticonvulsant that 
enhances the slow inactivation of voltage-gated sodium channels and is approved as 
adjunctive treatment for refractory focal-onset seizures. Although lacosamide can rarely cause 
a rash, there is no clear association with Stevens-Johnson syndrome.8 The clear improvement 
in paroxysmal tonic spasms seen in this woman with NMOSD suggests that lacosamide can 
be an alternative treatment option in situations where carbamazepine is contraindicated or 
poorly tolerated.  
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